While the benefits of pharmacological MR blockade on renal function and associated cardiovascular outcomes have been well described, it remains unclear how the MR in EC influences renal conduit and resistance vessel function in basal states and pathological conditions of hypertension and endothelial dysfunction. This evidence concerns the gene NR3C2 and endothelial dysfunction.